Pharmacological Approaches for Treatment-resistant Bipolar Disorder

Author(s): Shi Hui Poon, Kang Sim, Ross J. Baldessarini

Journal Name: Current Neuropharmacology

Volume 13 , Issue 5 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Bipolar disorder is prevalent, with high risks of disability, substance abuse and premature mortality. Treatment responses typically are incomplete, especially for depressive components, so that many cases can be considered “treatment resistant.” We reviewed reports on experimental treatments for such patients: there is a striking paucity of such research, mainly involving small incompletely controlled trials of add-on treatment, and findings remain preliminary. Encouraging results have been reported by adding aripiprazole, bupropion, clozapine, ketamine, memantine, pramipexole, pregabalin, and perhaps tri-iodothyronine in resistant manic or depressive phases. The urgency of incomplete responses in such a severe illness underscores the need for more systematic, simpler, and better controlled studies in more homogeneous samples of patients.

Keywords: Bipolar disorder, depression, experimental treatments, mania, treatment-resistance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 13 October, 2015
Page: [592 - 604]
Pages: 13
DOI: 10.2174/1570159X13666150630171954
Price: $65

Article Metrics

PDF: 37